BOA2018 Gastrointestinal

A number of recent studies have advanced knowledge about the treatment of gastrointestinal cancers. Converging evidence suggests that novel aspects of treatment such as radiation therapy boosts, chemoradiation vs. chemotherapy, preoperative chemoradiation therapy, novel targeted therapy combinations, novel biomarkers of response, and estimating and modeling toxicity of treatments are critical drivers of clinical practice. This session will highlight recent developments in these key areas, educating the audience about the clinical ramifications of these developments and thereby improve the quality of care by practicing physicians.

This session highlights recent studies exploring the value of preoperative chemoradiation therapy in borderline resectable pancreatic cancer patients, the role of a radiation boost in rectal cancer, the role of chemoradiation therapy in gastric cancers treated preoperatively or postoperatively, the toxicities arising from esophageal cancer radiotherapy and hepatobiliary proton radiotherapy, the value of monitoring circulating tumor DNA in pancreatic cancer patients, and the possible additional benefit of adding a PARP inhibitor to radiation therapy for pancreatic cancer. Collectively, this session identifies gaps in knowledge in key clinical practice arenas in gastrointestinal cancer radiation therapy, provides attendees with a nuanced understanding of the range of management options available in these circumstance, advances novel paradigms in the management of GI cancers commonly treated with radiation therapy and provides attendees with the opportunity to determine if these paradigms might affect their day-to-day practice.

Target Audience

The meeting is designed to meet the interests of radiation oncologists.

Learning Objectives

  • Define the role of preoperative chemoradiation therapy in borderline resectable pancreatic cancer.
  • Define the role of preoperative or postoperative chemoradiation therapy in gastric cancer.
  • Explain the causes and consequences of radiation-induced toxicity in esophageal and hepatobiliary cancers.
Course summary
Available credit: 
  • 1.00 SA-CME

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.

    The American Society for Radiation Oncology (ASTRO) designates this Live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.00 self-assessment credits.

  • 1.00 Certificate of Attendance
    This activity was designated for 1.00 AMA PRA Category 1 Credit™.
Course opens: 
11/16/2018
Course expires: 
12/07/2018
Cost:
$0.00
Rating: 
0

Sunil Krishnan, MD is employed by MD Anderson Cancer Center, receives compensation/remuneration/funding from  DoD, Celgene, Cancer Prevention and Research Institute of Texas, has ownership/investment interests in Taylor and Francis Group, and holds a leadership position in RTOG.

Catherine C. Park, MD, FASTRO is employed by UCSF, receives compensation/remuneration/funding from NIH, Oncosynergy LTD., has ownership/investment interests in Oncosynergy LTD., and holds a leadership position in UCSF.

The person(s) above served as the developer(s) of this activity. Additionally, Education Committee and CME/MOC Committee had control over the content of this activity.
 

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.

ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification. 

Available Credit

  • 1.00 SA-CME

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.

    The American Society for Radiation Oncology (ASTRO) designates this Live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.00 self-assessment credits.

  • 1.00 Certificate of Attendance
    This activity was designated for 1.00 AMA PRA Category 1 Credit™.

Accreditation Period

Course opens: 
11/16/2018
Course expires: 
12/07/2018

Price

Cost:
$0.00
Please login or register to take this course.

Policies: 

  • No refunds, extensions or substitutions will be made for those registrants who, for any reason, were unable to attend or were tardy for the session.
  • No credits will be granted and no refunds, exchanges or transfers will be given to those who do not pass.
  • ASTRO staff cannot make modifications to your submitted materials.
     

Required Hardware/software

One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.